Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.
Li N et al. Nat Commun. 2016 Nov 24;7:13656. doi: 10.1038/ncomms13656.
A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
Jiménez C et al. J Mol Diagn. 2016 Nov 15. pii: S1525-1578(16)30186-6. doi: 10.1016/j.jmoldx.2016.08.004. [Epub ahead of print].
Exome copy number variation detection: Use of a pool of unrelated healthy tissue as reference sample.
Wenric S et al. Genet Epidemiol. 2016 Nov 10. doi: 10.1002/gepi.22019. [Epub ahead of print].
Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo.
Xie B et al. Int J Mol Sci. 2016 Nov 17;17(11). pii: E1927.
Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy.
Yu W et al. Oncotarget. 2016 Nov 14. doi: 10.18632/oncotarget.13342. [Epub ahead of print].
Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA inmultiple myeloma.
Qin Y et al. Leukemia. 2016 Nov 18. doi: 10.1038/leu.2016.325. [Epub ahead of print].
Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.
Zhou H et al. Int J Hematol. 2016 Nov 15. [Epub ahead of print].
Lycorine induces cell death in MM by suppressing Janus Kinase/signal transducer and activator of transcription via inducing the expression of SOCS1.
Jin Z et al. Biomed Pharmacother. 2016 Nov 12. pii: S0753-3322(16)30990-8. doi: 10.1016/j.biopha.2016.10.069. [Epub ahead of print].
MiR-148a participates in the growth of RPMI8226 multiple myeloma cells by regulating CDKN1B.
Lang T et al. Biomed Pharmacother. 2016 Nov 11. pii: S0753-3322(16)30680-1. doi: 10.1016/j.biopha.2016.11.002. [Epub ahead of print].
IAP antagonists induce anti-tumor immunity in multiple myeloma.
Chesi M et al. Nat Med. 2016 Nov 14. doi: 10.1038/nm.4229. [Epub ahead of print].
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.
Sherbenou DW et al. J Clin Invest. 2016 Nov 14. pii: 85856. doi: 10.1172/JCI85856. [Epub ahead of print].
Peroxidase enzymes inhibit osteoclast differentiation and bone resorption.
Panagopoulos V et al. Mol Cell Endocrinol. 2016 Nov 9;440:8-15. doi: 10.1016/j.mce.2016.11.007. [Epub ahead of print].
Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma.
Spanoudakis E et al. Blood Cancer J. 2016 Nov 11;6(11):e500. doi: 10.1038/bcj.2016.108.
Proteomic Characterization of the World Trade Center dust-activated mdig and c-myc signaling circuit linked to multiple myeloma.
Wu K et al. Sci Rep. 2016 Nov 11;6:36305. doi: 10.1038/srep36305.
MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma.
Zhang X et al. Leuk Lymphoma. 2016 Nov 10:1-9. [Epub ahead of print].
Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myelomareveals alterations related to relapse.
Krzeminski P et al. Oncotarget. 2016 Nov 2. doi: 10.18632/oncotarget.13025. [Epub ahead of print].
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.
Zelle-Rieser C et al. J Hematol Oncol. 2016 Nov 3;9(1):116.
Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.
Malek E et al. Leukemia. 2016 Nov 4. doi: 10.1038/leu.2016.258. [Epub ahead of print].
Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma.
Gutiérrez-González A et al. Blood. 2016 Nov 3;128(18):2241-2252.
Assessing Heterogeneity of Osteolytic Lesions in Multiple Myeloma by ¹H HR-MAS NMR Metabolomics.
Tavel L et al. Int J Mol Sci. 2016 Oct 31;17(11). pii: E1814.
The Low Expression of IL-37 Involved in Multiple Myeloma – Associated Angiogenesis.
Li ZC et al. Med Sci Monit. 2016 Nov 3;22:4164-4168.
Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.
Lohr JG et al. Sci Transl Med. 2016 Nov 2;8(363):363ra147.
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG et al. Oncotarget. 2016 Oct 28. doi: 10.18632/oncotarget.12969. [Epub ahead of print].
3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
Lee HY et al. Eur J Med Chem. 2016 Nov 15;125:1268-1278. doi: 10.1016/j.ejmech.2016.11.033. [Epub ahead of print].
Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma.
Bordini J et al. Leukemia. 2016 Nov 24. doi: 10.1038/leu.2016.346. [Epub ahead of print].